US Stock MarketDetailed Quotes

IMNPQ Immune Pharmaceuticals, Inc.

Watchlist
  • 0.001000
  • 0.0000000.00%
15min DelayClose Oct 25 09:30 ET
172.88KMarket Cap0.00P/E (TTM)

Immune Pharmaceuticals, Inc. Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2018
(Q2)Jun 30, 2018
(Q1)Mar 31, 2018
(FY)Dec 31, 2017
(Q4)Dec 31, 2017
(Q3)Sep 30, 2017
(Q2)Jun 30, 2017
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-95.68%-1.5M
-102.37%-3.16M
-3.69M
-11.56M
-6.34M
-764K
-1.56M
Net income from continuing operations
31.71%-4.13M
4.44%-4.72M
---4.38M
---17.89M
---3.15M
---6.05M
---4.94M
Operating gains losses
--0
----
----
--2.47M
--58K
--2.15M
----
Depreciation and amortization
-18.36%209K
203.95%231K
--230K
--657K
--230K
--256K
--76K
Deferred tax
----
----
----
---1.79M
----
----
----
Other non cash items
-47.53%489K
-32.02%1.38M
--77K
--5.04M
--1.55M
--932K
--2.03M
Change In working capital
8.79%1.93M
-151.46%-565K
--303K
---571K
---3.42M
--1.77M
--1.1M
-Change in payables and accrued expense
5.08%1.99M
-172.56%-550K
--263K
---869K
---3.54M
--1.89M
--758K
-Change in other current assets
51.28%-57K
-104.41%-15K
--40K
--298K
--114K
---117K
--340K
Cash from discontinued investing activities
Operating cash flow
-95.68%-1.5M
-102.37%-3.16M
---3.69M
---11.56M
---6.34M
---764K
---1.56M
Investing cash flow
Cash flow from continuing investing activities
-38K
-150.85%-30K
-31K
31K
-6K
0
59K
Net PPE purchase and sale
---38K
---30K
---31K
---28K
---6K
--0
--0
Net other investing changes
----
----
----
--59K
--0
--0
----
Cash from discontinued investing activities
Investing cash flow
---38K
-150.85%-30K
---31K
--31K
---6K
--0
--59K
Financing cash flow
Cash flow from continuing financing activities
-87.65%101K
35.62%1.96M
-319K
18.03M
13.05M
818K
1.45M
Net issuance payments of debt
-88.57%100K
158.26%2.01M
---205K
---2.43M
---2.98M
--875K
---3.45M
Net common stock issuance
----
----
----
--0
----
----
----
Net preferred stock issuance
----
----
----
--16.04M
----
----
----
Cash dividends paid
---2K
---46K
---114K
---16K
---16K
--0
--0
Proceeds from stock option exercised by employees
----
----
----
--0
--0
----
----
Net other financing activities
----
----
----
--4.44M
--0
---57K
--4.89M
Cash from discontinued financing activities
Financing cash flow
-87.65%101K
35.62%1.96M
---319K
--18.03M
--13.05M
--818K
--1.45M
Net cash flow
Beginning cash position
6,754.55%1.51M
2,363.06%2.73M
--6.78M
--271K
--76K
--22K
--111K
Current changes in cash
-2,751.85%-1.43M
-2,129.09%-1.23M
---4.04M
--6.51M
--6.7M
--54K
---55K
End cash Position
0.00%76K
6,754.55%1.51M
--2.73M
--6.78M
--6.78M
--76K
--22K
Free cash flow
-100.65%-1.53M
-104.29%-3.19M
---3.72M
---11.59M
---6.35M
---764K
---1.56M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
(Q3)Sep 30, 2018(Q2)Jun 30, 2018(Q1)Mar 31, 2018(FY)Dec 31, 2017(Q4)Dec 31, 2017(Q3)Sep 30, 2017(Q2)Jun 30, 2017
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -95.68%-1.5M-102.37%-3.16M-3.69M-11.56M-6.34M-764K-1.56M
Net income from continuing operations 31.71%-4.13M4.44%-4.72M---4.38M---17.89M---3.15M---6.05M---4.94M
Operating gains losses --0----------2.47M--58K--2.15M----
Depreciation and amortization -18.36%209K203.95%231K--230K--657K--230K--256K--76K
Deferred tax ---------------1.79M------------
Other non cash items -47.53%489K-32.02%1.38M--77K--5.04M--1.55M--932K--2.03M
Change In working capital 8.79%1.93M-151.46%-565K--303K---571K---3.42M--1.77M--1.1M
-Change in payables and accrued expense 5.08%1.99M-172.56%-550K--263K---869K---3.54M--1.89M--758K
-Change in other current assets 51.28%-57K-104.41%-15K--40K--298K--114K---117K--340K
Cash from discontinued investing activities
Operating cash flow -95.68%-1.5M-102.37%-3.16M---3.69M---11.56M---6.34M---764K---1.56M
Investing cash flow
Cash flow from continuing investing activities -38K-150.85%-30K-31K31K-6K059K
Net PPE purchase and sale ---38K---30K---31K---28K---6K--0--0
Net other investing changes --------------59K--0--0----
Cash from discontinued investing activities
Investing cash flow ---38K-150.85%-30K---31K--31K---6K--0--59K
Financing cash flow
Cash flow from continuing financing activities -87.65%101K35.62%1.96M-319K18.03M13.05M818K1.45M
Net issuance payments of debt -88.57%100K158.26%2.01M---205K---2.43M---2.98M--875K---3.45M
Net common stock issuance --------------0------------
Net preferred stock issuance --------------16.04M------------
Cash dividends paid ---2K---46K---114K---16K---16K--0--0
Proceeds from stock option exercised by employees --------------0--0--------
Net other financing activities --------------4.44M--0---57K--4.89M
Cash from discontinued financing activities
Financing cash flow -87.65%101K35.62%1.96M---319K--18.03M--13.05M--818K--1.45M
Net cash flow
Beginning cash position 6,754.55%1.51M2,363.06%2.73M--6.78M--271K--76K--22K--111K
Current changes in cash -2,751.85%-1.43M-2,129.09%-1.23M---4.04M--6.51M--6.7M--54K---55K
End cash Position 0.00%76K6,754.55%1.51M--2.73M--6.78M--6.78M--76K--22K
Free cash flow -100.65%-1.53M-104.29%-3.19M---3.72M---11.59M---6.35M---764K---1.56M
Currency Unit USDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion with Explanatory Notes------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg